Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

RACE-SEQ and Population-Wide Polymorphism Susceptibility Testing for Endonucleolytically Active, RNA-Targeting Therapeutics.

Usher L, Theotokis PI, Moschos SA.

Methods Mol Biol. 2019;2036:283-305. doi: 10.1007/978-1-4939-9670-4_17.

PMID:
31410804
2.

Measuring the Action of Oligonucleotide Therapeutics in the Lung at the Cell Type-Specific Level by Tissue Disruption and Cell Sorting (TDCS).

Graves H, Evans S, Fauler M, Frick M, Moschos SA.

Methods Mol Biol. 2019;2036:187-203. doi: 10.1007/978-1-4939-9670-4_11.

PMID:
31410798
3.

Extracellular vesicles and their nucleic acids for biomarker discovery.

Momen-Heravi F, Getting SJ, Moschos SA.

Pharmacol Ther. 2018 Dec;192:170-187. doi: 10.1016/j.pharmthera.2018.08.002. Epub 2018 Aug 3. Review.

PMID:
30081050
4.

A novel antifungal property for the Bacillus licheniformis ComX pheromone and its possible role in inter-kingdom cross-talk.

Esmaeilishirazifard E, Dariush A, Moschos SA, Keshavarz T.

Appl Microbiol Biotechnol. 2018 Jun;102(12):5197-5208. doi: 10.1007/s00253-018-9004-7. Epub 2018 Apr 23.

PMID:
29687141
5.

Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs.

Theotokis PI, Usher L, Kortschak CK, Schwalbe E, Moschos SA.

Mol Ther Nucleic Acids. 2017 Dec 15;9:22-33. doi: 10.1016/j.omtn.2017.08.010. Epub 2017 Aug 24.

6.

Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?

Kumar M, Moschos SA.

Mol Ther. 2017 Dec 6;25(12):2604-2606. doi: 10.1016/j.ymthe.2017.11.002. Epub 2017 Nov 23. No abstract available.

7.

Field-deployable, quantitative, rapid identification of active Ebola virus infection in unprocessed blood.

Shah K, Bentley E, Tyler A, Richards KSR, Wright E, Easterbrook L, Lee D, Cleaver C, Usher L, Burton JE, Pitman JK, Bruce CB, Edge D, Lee M, Nazareth N, Norwood DA, Moschos SA.

Chem Sci. 2017 Nov 1;8(11):7780-7797. doi: 10.1039/c7sc03281a. Epub 2017 Sep 25.

8.

Genomic and molecular characterization of a novel quorum sensing molecule in Bacillus licheniformis.

Esmaeilishirazifard E, De Vizio D, Moschos SA, Keshavarz T.

AMB Express. 2017 Dec;7(1):78. doi: 10.1186/s13568-017-0381-6. Epub 2017 Apr 8.

9.

Clinical potential of oligonucleotide-based therapeutics in the respiratory system.

Moschos SA, Usher L, Lindsay MA.

Pharmacol Ther. 2017 Jan;169:83-103. doi: 10.1016/j.pharmthera.2016.10.009. Epub 2016 Oct 19. Review.

PMID:
27771436
10.

Ebola Check: Delivering molecular diagnostics at the point of need.

Moschos SA.

Hell J Nucl Med. 2015 Sep-Dec;18 Suppl 1:144.

11.

Introducing EbolaCheck: potential for point-of-need infectious disease diagnosis.

Moschos SA.

Expert Rev Mol Diagn. 2015;15(10):1237-40. doi: 10.1586/14737159.2015.1084228. Epub 2015 Sep 1.

PMID:
26327281
12.

Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision.

Denise H, Moschos SA, Sidders B, Burden F, Perkins H, Carter N, Stroud T, Kennedy M, Fancy SA, Lapthorn C, Lavender H, Kinloch R, Suhy D, Corbau R.

Mol Ther Nucleic Acids. 2014 Feb 4;3:e145. doi: 10.1038/mtna.2013.73.

13.

Genomic biomarkers for patient selection and stratification: the cancer paradigm.

Moschos SA.

Bioanalysis. 2012 Oct;4(20):2499-511. doi: 10.4155/bio.12.241. Review.

PMID:
23157358
14.

Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.

Suhy DA, Kao SC, Mao T, Whiteley L, Denise H, Souberbielle B, Burdick AD, Hayes K, Wright JF, Lavender H, Roelvink P, Kolykhalov A, Brady K, Moschos SA, Hauck B, Zelenaia O, Zhou S, Scribner C, High KA, Renison SH, Corbau R.

Mol Ther. 2012 Sep;20(9):1737-49. doi: 10.1038/mt.2012.119. Epub 2012 Jun 26.

15.

Relevance of systems pharmacology in drug discovery.

Cucurull-Sanchez L, Spink KG, Moschos SA.

Drug Discov Today. 2012 Jul;17(13-14):665-70. doi: 10.1016/j.drudis.2012.01.015. Epub 2012 Jan 25.

PMID:
22405899
16.

Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.

Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, Weber M, Lazari O, Perez-Tosar L, Fancy SA, Lapthorn C, Green MX, Evans S, Selby M, Jones G, Jones L, Kearney S, Mechiche H, Gikunju D, Subramanian R, Uhlmann E, Jurk M, Vollmer J, Ciaramella G, Yeadon M.

Mol Ther. 2011 Dec;19(12):2163-8. doi: 10.1038/mt.2011.206. Epub 2011 Oct 4.

17.

Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma.

Tsitsiou E, Williams AE, Moschos SA, Patel K, Rossios C, Jiang X, Adams OD, Macedo P, Booton R, Gibeon D, Chung KF, Lindsay MA.

J Allergy Clin Immunol. 2012 Jan;129(1):95-103. doi: 10.1016/j.jaci.2011.08.011. Epub 2011 Sep 13.

PMID:
21917308
18.

Measuring the action of CPP-siRNA conjugates in the lung.

Moschos SA, Spink KG, Lindsay MA.

Methods Mol Biol. 2011;683:417-29. doi: 10.1007/978-1-60761-919-2_30.

PMID:
21053147
19.

Targeting the lung using siRNA and antisense based oligonucleotides.

Moschos SA, Spinks K, Williams AE, Lindsay MA.

Curr Pharm Des. 2008;14(34):3620-7. Review.

PMID:
19075738
20.

Role of miRNA-146a in the regulation of the innate immune response and cancer.

Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA.

Biochem Soc Trans. 2008 Dec;36(Pt 6):1211-5. doi: 10.1042/BST0361211. Review.

PMID:
19021527
21.

Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells.

Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA.

J Immunol. 2008 Apr 15;180(8):5689-98.

22.

Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.

Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, Barnes PJ, Sproat BS, Gait MJ, Lindsay MA.

Bioconjug Chem. 2007 Sep-Oct;18(5):1450-9. Epub 2007 Aug 21.

24.

Cell-penetrating-peptide-mediated siRNA lung delivery.

Moschos SA, Williams AE, Lindsay MA.

Biochem Soc Trans. 2007 Aug;35(Pt 4):807-10. Review.

PMID:
17635153
25.

microRNA expression in the aging mouse lung.

Williams AE, Perry MM, Moschos SA, Lindsay MA.

BMC Genomics. 2007 Jun 15;8:172.

26.

MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity.

Turner JJ, Jones SW, Moschos SA, Lindsay MA, Gait MJ.

Mol Biosyst. 2007 Jan;3(1):43-50. Epub 2006 Nov 20.

27.

Maternally imprinted microRNAs are differentially expressed during mouse and human lung development.

Williams AE, Moschos SA, Perry MM, Barnes PJ, Lindsay MA.

Dev Dyn. 2007 Feb;236(2):572-80.

28.

Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A.

Moschos SA, Bramwell VW, Somavarapu S, Alpar HO.

Vaccine. 2006 Feb 20;24(8):1081-6. Epub 2005 Sep 19.

PMID:
16219395
29.

Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation.

Moschos SA, Bramwell VW, Somavarapu S, Alpar HO.

Vaccine. 2005 Mar 14;23(16):1923-30.

PMID:
15734064
30.

Adjuvant synergy: the effects of nasal coadministration of adjuvants.

Moschos SA, Bramwell VW, Somavarapu S, Alpar HO.

Immunol Cell Biol. 2004 Dec;82(6):628-37.

PMID:
15550121

Supplemental Content

Loading ...
Support Center